Shire Inks $5.2B Deal For US Biotech NPS Pharma
Shire PLC said Sunday it will buy New Jersey-based rare disease biotech NPS Pharmaceuticals Inc. in a $5.2 billion all-cash transaction, a deal that comes three months after the British drugmaker's...To view the full article, register now.
Already a subscriber? Click here to view full article